Shares of West Pharmaceutical Servs WST remained unaffected after the company reported Q2 results.
Quarterly Results
Earnings per share rose 96.80% over the past year to $2.46, which beat the estimate of $1.74.
Revenue of $723,600,000 rose by 37.25% from the same period last year, which beat the estimate of $669,380,000.
Outlook
The upcoming fiscal year's EPS expected to be between $8.05 and $8.20.
The upcoming fiscal year's revenue expected to be between $2,760,000,000 and $2,785,000,000.
How To Listen To The Conference Call
Date: Jul 29, 2021
Time: 09:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/f966zihe
Technicals
52-week high: $385.30
52-week low: $253.85
Price action over last quarter: Up 16.89%
Company Overview
West Pharmaceutical Services is a Pennsylvania-based medical supplies company that operates as a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West develops, manufactures, and distributes elastomer-based supplies for the containment and administration of injectable drugs, including basic equipment such as syringes, stoppers, and plungers, along with somewhat more complicated devices including auto-injectors and other self-injection platforms. The company reports in two segments: proprietary products (77% of 2020 sales) and contract-manufactured products (23%). It generates 55% of its revenue from international markets and 45% from the United States.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.